👋 Hey, let’s get into it. A few years ago, anti-aging biotech mostly lived somewhere between science fiction and venture capital PowerPoints. And let's be honest: when scientists hear "anti-aging," many immediately become skeptical thanks to an endless parade of influencers selling miracle supplements and longevity hacks.

This week, NewLimit raised $435 million after reaching a clinic-ready candidate years ahead of schedule. The company uses combinations of transcription factors delivered via mRNA to help aged liver cells behave more youthfully. Management expected the discovery process to take years, but its screening platform identified a promising candidate within months.

The result? A longevity startup with a phase 1 trial in sight, a fresh pile of cash, and ambitions extending far beyond the liver.

💰 Lilly and Boehringer Slash More Than $2B in Planned German Investments
Germany's proposed healthcare reforms just received a very expensive vote of no confidence. Eli Lilly plans to cut its previously announced €2.3 billion ($2.7 billion) German investment roughly in half, while Boehringer Ingelheim is trimming another €900 million ($1 billion). Both companies say the reforms would create uncertainty and force deeper discounts on branded medicines. Lilly CEO David Ricks suggested some of that capital may instead head to U.S. manufacturing projects. When governments try to lower drug spending, pharma sometimes responds with the corporate version of "fine, we'll spend our money somewhere else."

🤑 Celcuity Says Gedatolisib Breast Cancer Data Could Put It on a $10B Path
Celcuity arrived at ASCO with numbers. Its PAM pathway inhibitor gedatolisib roughly doubled progression-free survival in advanced breast cancer patients carrying PIK3CA mutations and outperformed Novartis' Piqray. The drug attacks the entire PI3K/AKT/mTOR pathway instead of targeting individual components, an approach many researchers viewed as too difficult to execute. CEO Brian Sullivan now believes the program could help build a $10 billion company. Ambitious? Absolutely. But biotech history is filled with companies that looked crazy right before they looked right.

🤝 Lilly and Ascidian Sign RNA Exon Editing Partnership Worth Up to $1.9B
Lilly continues its genetic medicines shopping spree. The pharma giant partnered with Ascidian in a deal worth up to $1.9 billion to develop RNA exon editing therapies for genetic kidney diseases. Unlike DNA editing approaches, Ascidian's platform aims to repair RNA transcripts without permanently altering the genome. The technology remains early, but Lilly clearly sees enough potential to place a very large bet. Kidney disease continues to attract major investment as companies search for the next breakthrough beyond obesity and oncology.

🏔️ Travere Pays $112.5M Upfront for Everest's Rare Kidney Disease BTK Inhibitor
Rare kidney disease assets remain hot. Travere Therapeutics agreed to pay $112.5 million upfront and up to $1.03 billion in milestones for civorebrutinib, a BTK inhibitor licensed from Everest Medicines. The therapy is already in clinical development and could potentially address conditions including IgA nephropathy and focal segmental glomerulosclerosis. For Travere, the deal expands an increasingly focused kidney disease portfolio. For Everest, it's another example of Chinese-developed assets finding global partners.

📈 Legend Biotech Jumps 42% After In Vivo CAR-T Delivers 100% Response Rate
Six patients. Six responses. That's enough to get Wall Street's attention. Legend Biotech reported a 100% objective response rate and an 83% complete response rate for its in vivo CAR-T candidate LB2501 in early-stage lymphoma testing. Analysts quickly labeled the therapy potentially best-in-class and speculated the company could become a takeover target. Investors responded by sending shares up 42% in a single day. Small datasets require caution, but those are the kinds of numbers that make dealmakers start updating spreadsheets.

🎯 Bristol Myers' $800M Bispecific ADC Cuts Death Risk by 40% in Triple-Negative Breast Cancer
The EGFRxHER3 ADC acquired from China's Biokin delivered strong phase 3 results and could challenge the TROP2 leaders.

💉 Moderna's Personalized Melanoma Vaccine Delivers 5-Year Survival Win
Paired with Keytruda, Moderna's mRNA vaccine reduced recurrence or death risk by 49% after five years.

⚠️ Abivax Shares Crash 28% Despite Best-in-Class Ulcerative Colitis Data
Strong remission results were overshadowed after cancers emerged among several patients receiving higher-dose treatment.

💸 Regeneron Expands CytomX Alliance to Nearly $4B in Potential Value
The expanded cancer collaboration adds new targets and gives Regeneron options on multiple future programs.

📉 Fulcrum Falls More Than 50% After FDA Raises Cancer Concerns
The biotech discontinued its lead sickle cell program after regulators questioned its benefit-risk profile.

For years, Western biotech viewed China as a source of cheaper development, faster trials, and the occasional licensing opportunity. ASCO 2026 made something very clear: that era is over.

The conference's biggest moments were increasingly tied to Chinese companies and Chinese-developed assets. Akeso landed a coveted plenary presentation with ivonescimab. Kelun's TROP2 ADC generated potentially practice-changing data. Innovent walked into ASCO fresh off a major Pfizer partnership. And Takeda, Merck, Bristol Myers Squibb, BioNTech, and others all spent considerable time explaining why they're sourcing more innovation from China.

The numbers tell the story. Cross-border licensing activity involving Chinese biotech assets has exploded. Upfront deal values have climbed roughly 400% since 2022, reaching billions of dollars annually. What was once viewed as a discount marketplace has become a premium innovation hub. As one industry observer put it, China is no longer the bargain basement.

The shift isn't happening because regulators are moving faster. In some cases, the FDA remains quicker. Instead, Chinese companies have built increasingly sophisticated discovery engines, streamlined preclinical operations, and clinical development ecosystems capable of generating competitive data at remarkable speed. Even Pfizer CEO Albert Bourla has acknowledged that Chinese companies may soon become more productive than many Western peers at early-stage innovation.

That doesn't mean every question has been answered. Global validation remains critical. Several experts at ASCO emphasized that positive Chinese studies still need confirmation across broader patient populations. Geopolitical tensions also continue to loom over cross-border collaboration.

Still, the direction of travel feels obvious. Ten years ago, Chinese biotech hoped to produce its first global success story. Today, multinational pharma companies are competing to secure access to the next one. The conversation has shifted from "Can China innovate?" to "Can everyone else keep up?"

That's how many meals Eisai had delivered through its Magnolia Meals program as of January. The initiative provides medically tailored meals and nutrition support to patients facing serious illnesses, helping address food insecurity and the practical challenges that can interfere with treatment and recovery. Originally launched for cancer patients, the program is now expanding into Alzheimer's disease and related dementias. It's a reminder that healthcare isn't just drugs and clinical trials. Sometimes improving outcomes starts with helping people eat dinner. 🍽️

Here’s what biotech Redditors are talking about:

😬 “We Can Cancel Any Grant at Any Time”
A Reddit discussion about proposed U.S. research funding changes quickly turned existential. Commenters questioned whether peer review could lose influence while political oversight gains power. Several researchers described funding losses, lab closures, and colleagues relocating abroad. One former investigator claimed their lab lost 40% of its funding before moving operations to Europe. The overall mood ranged from frustration to outright panic, with many arguing America's scientific advantage is becoming less certain.

🤖 Scientists Push Back on Protein-Folding AI Skepticism
A post highlighting a new protein-folding AI capable of predicting structures for one billion proteins attracted plenty of skepticism. The most popular response sarcastically questioned whether any of the predictions were correct. Researchers in the field pushed back, explaining that modern protein prediction systems routinely perform exceptionally well in benchmark competitions. The consensus was nuanced: today's models are incredibly useful, but predicting proteins in their dynamic biological environments remains one of the field's biggest unsolved challenges.

🦠 Merck Considers Repurposing Lagevrio for Ebola
The COVID antiviral may get a second act as health authorities evaluate options for a worsening Ebola outbreak.

🏭 Pharma Manufacturing Could Add 19,000 U.S. Jobs by 2034
Federal projections place drug manufacturing among America's fastest-growing manufacturing sectors over the next decade.

🏥 Lilly Issues Data-Sharing Ultimatum to 340B Hospitals
Hospitals refusing to provide claims data could lose access to Lilly's discounted drug pricing programs.

📉 Massachusetts Life Sciences Hiring Goals Fall Well Short
Seventeen incentivized companies added just 41 net jobs despite plans calling for more than 400.

🍆 Contraline Raises $92.5M to Advance Male Birth Control Programs
For decades, the conversation around contraception has focused almost entirely on women. Contraline wants to change that. The company just raised $92.5 million to push its hormone-based male contraceptive gel, NES/T, toward phase 3 development. The product combines a synthetic progestin with testosterone to suppress sperm production while maintaining normal hormone levels. With no medication-based male contraceptive currently on the market, Contraline is pursuing one of healthcare's largest untapped opportunities. Investors clearly think the market is ready.

📨 June 4, 1924 — The Ultimate “Ask for the Manager” Move
After having his manuscript rejected, physicist Satyendra Nath Bose decided not to quietly accept defeat. Instead, he mailed the paper directly to Albert Einstein. Einstein immediately recognized its importance, translated the work into German, and helped get it published. The breakthrough ultimately laid the foundation for Bose-Einstein statistics and the discovery of bosons. The lesson? Sometimes the difference between a rejection and a breakthrough is who gets the email.

Some people get rejected and move on. Bose got rejected and contacted Einstein. NewLimit expected years of work and found a drug candidate in months. Maybe the lesson here is that occasionally ignoring expectations works out surprisingly well. Just maybe don't start emailing Nobel Prize winners at random…unless you want to forward them BioNucleus Briefing. 😁

That’s all for today. See you Tuesday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead